Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state

Insights

Nitrendipine potently blocks calcium (Ca2+) channels in their inactivated state, not their resting state. This explains high-affinity [3H]nitrendipine binding to inactivated Ca2+ channels in cardiac cells.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Pharmacology
  • Ion Channel Biophysics

Background:

  • Dihydropyridine drugs, like nitrendipine, are known to affect calcium (Ca2+) channel activity.
  • Understanding the precise binding states of drugs to ion channels is crucial for pharmacology.
  • Previous studies indicated high-affinity binding of [3H]nitrendipine to tissue membranes.

Purpose of the Study:

  • To investigate the mechanism of calcium (Ca2+) current block by nitrendipine in canine ventricular cells.
  • To determine the binding affinity of nitrendipine to different states of the Ca2+ channel.
  • To correlate drug binding with known high-affinity radioligand binding sites.

Main Methods:

  • Whole-cell patch clamp technique applied to single canine ventricular cells.
  • Measurement of Ca2+ currents under varying membrane potentials (depolarized and hyperpolarized).
  • Analysis of nitrendipine concentration-dependent block and apparent dissociation constants (Kd).

Main Results:

  • Nitrendipine exhibited potent block of Ca2+ currents at depolarized potentials (70% inactivated state) with a Kd of 0.36 nM.
  • Block was significantly less potent at hyperpolarized potentials (resting state) with a Kd of approximately 700 nM.
  • Observed binding kinetics and affinity align with high-affinity [3H]nitrendipine binding to membrane fragments.

Conclusions:

  • Nitrendipine preferentially binds to the inactivated state of the Ca2+ channel.
  • The high-affinity [3H]nitrendipine binding site likely represents the inactivated state of the Ca2+ channel.
  • This provides a mechanistic link between drug action and radioligand binding studies.

Related Concept Videos

Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...